Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders.

Medical oncology (Northwood, London, England) - 1 Jan 2001

Pangalis G A, Dimopoulou M N, Angelopoulou M K, Tsekouras C, Vassilakopoulos T P, Vaiopoulos G, Siakantaris M P

Abstract excerpt

Campath-1H is a humanized monoclonal antibody targeted against the CDw52 membrane antigen of lymphocytes, which causes complement and antibody-dependent cell-mediated cytotoxicity. Campath-1H has been used in B-chronic lymphocytic leukemia (B-CLL), T-prolymphocytic leukemia (T-PLL), and low-grade non-Hodgkin's lymphoma (LGNHL). Campath-1H is administered intravenously thrice weekly for up to 12 wk, at an initial...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Antibodies, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunosuppression Therapy

Share to Infections

Share to Infusions, Intravenous

Share to Interleukin-6

Share to Leukemia, B-Cell

Share to Lymphoma, Non-Hodgkin

Source

Identifiers

PMID: 11778765
DOI: 10.1385/mo:18:2:99

Genes

TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders.PMID 11778765Read ↗

Phenotypic transformation of CD52(pos) to CD52(neg) leukemic T cells as a mechanism for resistance to CAMPATH-1H.Semantic proximity Read ↗

Improved biodistribution, tumor targeting, and reduced immunogenicity in mice with a gamma 4 variant of Campath-1H.Semantic proximity Read ↗

Antibody therapy for chronic lymphocytic leukemia.Semantic proximity Read ↗

CD52 (CAMPATH1).Semantic proximity Read ↗

The role of high-dose corticosteroids in the treatment of chronic lymphocytic leukemia.Semantic proximity Read ↗

The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia–Microenvironment Interactions in Chronic Lymphocytic LeukemiaSemantic proximity Read ↗

Cellular Cytotoxicity of Next-Generation CD20 Monoclonal AntibodiesSemantic proximity Read ↗

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.Semantic proximity Read ↗

Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies.Semantic proximity Read ↗

A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.Semantic proximity Read ↗

Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapySemantic proximity Read ↗

The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-Cell leukemia/lymphoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.